<DOC>
	<DOC>NCT02536300</DOC>
	<brief_summary>This study will optimize the safety and efficacy of chronic administration of idelalisib in participants with follicular lymphoma (FL) and evaluate the overall safety profile of idelalisib and the overall response rate (ORR) by Week 24.</brief_summary>
	<brief_title>Dose Optimization Study of Idelalisib in Follicular Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma, Follicular</mesh_term>
	<mesh_term>Idelalisib</mesh_term>
	<criteria>Key Histologically confirmed diagnosis of Bcell follicular lymphoma (FL), and grade limited to 1, 2, or 3a based on criteria established by the WHO 2008 classification of tumors of hematopoietic and lymphoid tissues Refractory to and disease progression within 6 months from the last dose of at least 2 lines of prior therapy AnnArbor Stage 2 (noncontiguous), 3, or 4 disease per Lugano Classification Radiographically measurable lymphadenopathy or extranodal lymphoid malignancy (defined as the presence of ≥ 1 lesion that measures ≥ 1.5 cm in the longest dimension (LD) and ≥ 1.0 cm in the longest perpendicular dimension (LPD) as assessed by positron emission tomographycomputed tomography (PETCT), computed tomography (CT) or magnetic resonance imaging (MRI) Required baseline central laboratory data in protocol. For female individuals of childbearing potential and male individuals of reproductive potential, willingness to use a protocol recommended method of contraception Lactating females must agree to discontinue nursing Willing and able to comply with scheduled visits, drug administration plan, imaging studies, laboratory tests, other study procedures, and study restrictions including mandatory prophylaxis for Pneumocystis jirovecii pneumonia (PJP) Key History of lymphoid malignancy other than FL (eg, diffuse large Bcell lymphoma) Known history of, or clinically apparent, central nervous system (CNS) lymphoma or leptomeningeal lymphoma. Known presence of intermediate or highgrade myelodysplastic syndrome. Known history of serious allergic reaction including anaphylaxis or Stevens Johnson syndrome/ toxic epidermal necrolysis History of a nonlymphoid malignancy except for protocol allowed exceptions Evidence of ongoing systemic bacterial, fungal, or viral infection at the time of enrollment Known history of druginduced liver injury, chronic active hepatitis B virus (HBV), chronic active hepatitis C virus (HCV), alcoholic liver disease, nonalcoholic steatohepatitis, cirrhosis of the liver, portal hypertension, primary biliary cirrhosis, or ongoing extrahepatic obstruction caused by cholelithiasis History of or ongoing druginduced pneumonitis History of or ongoing inflammatory bowel disease Known human immunodeficiency virus (HIV) infection History of prior allogeneic bone marrow progenitor cell or solid organ transplantation Ongoing immunosuppressive therapy, including systemic corticosteroids (&gt; 10 mg prednisone or equivalent/day) with the exception of the use of topical, enteric, or inhaled corticosteroids as therapy for comorbid conditions and systemic steroids for autoimmune anemia and/or thrombocytopenia Concurrent participation in another therapeutic clinical trial Prior treatment with phosphatidylinositol 3kinase (PI3K) delta inhibitors, Bruton's tyrosine kinase (BTK) inhibitors, janus kinase inhibitor (JAK) inhibitors, mammalian target of rapamycin (mTOR) inhibitors, or spleen tyrosine kinase (Syk) inhibitors Cytomegalovirus (CMV) Ongoing infection, treatment, or prophylaxis within the past 28 days NOTE: Other protocol defined Inclusion/ Exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>